丁丙诺啡用于新生儿戒断综合征
Buprenorphine in Neonatal Abstinence Syndrome.
作者信息
Kraft Walter K
机构信息
Sidney Kimmel Medical College of Thomas Jefferson University, Department of Pharmacology and Experimental Medicine, Philadelphia, Pennsylvania, USA.
出版信息
Clin Pharmacol Ther. 2018 Jan;103(1):112-119. doi: 10.1002/cpt.930. Epub 2017 Nov 28.
Abstract
Infants exposed in utero to opioids will demonstrate a withdrawal syndrome known as neonatal abstinence syndrome (NAS). Buprenorphine is a long-acting opioid with therapeutic use in medication-assisted treatment of opioid dependency in adults and adolescents. Emerging data from clinical trials and treatment cohorts demonstrate the efficacy and safety of sublingual buprenorphine for those infants with NAS who require pharmacologic treatment. Pharmacometric modeling will assist in defining the exposure-response relationships and facilitate dose optimization.
摘要
子宫内接触阿片类药物的婴儿会出现一种称为新生儿戒断综合征（NAS）的戒断综合征。丁丙诺啡是一种长效阿片类药物，在成人和青少年阿片类药物依赖的药物辅助治疗中具有治疗用途。来自临床试验和治疗队列的新数据表明，舌下含服丁丙诺啡对那些需要药物治疗的NAS婴儿具有疗效和安全性。药代动力学建模将有助于确定暴露-反应关系并促进剂量优化。
相似文献
1
Buprenorphine in Neonatal Abstinence Syndrome.丁丙诺啡用于新生儿戒断综合征
Clin Pharmacol Ther. 2018 Jan;103(1):112-119. doi: 10.1002/cpt.930. Epub 2017 Nov 28.
2
Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome.修订的舌下丁丙诺啡治疗新生儿阿片类戒断综合征的剂量方案。
Addiction. 2011 Mar;106(3):574-80. doi: 10.1111/j.1360-0443.2010.03170.x. Epub 2010 Oct 6.
3
Time to initiation of treatment for neonatal abstinence syndrome in neonates exposed in utero to buprenorphine or methadone.接受丁丙诺啡或美沙酮宫内暴露的新生儿戒断综合征的治疗开始时间。
Drug Alcohol Depend. 2013 Nov 1;133(1):266-9. doi: 10.1016/j.drugalcdep.2013.06.004. Epub 2013 Jul 8.
4
Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial.舌下含服丁丙诺啡治疗新生儿戒断综合征：一项随机试验。
Pediatrics. 2008 Sep;122(3):e601-7. doi: 10.1542/peds.2008-0571. Epub 2008 Aug 11.
5
Design considerations for point-of-care clinical trials comparing methadone and buprenorphine treatment for opioid dependence in pregnancy and for neonatal abstinence syndrome.关于比较美沙酮和丁丙诺啡治疗妊娠期间阿片类药物依赖及新生儿戒断综合征的即时医疗临床试验的设计考量
Contemp Clin Trials. 2014 Sep;39(1):158-65. doi: 10.1016/j.cct.2014.08.009. Epub 2014 Aug 23.
6
Neonatal Abstinence Syndrome: Presentation and Treatment Considerations.新生儿戒断综合征：临床表现与治疗注意事项。
J Addict Med. 2016 Jul-Aug;10(4):224-8. doi: 10.1097/ADM.0000000000000222.
7
Interventions for the Treatment of Neonatal Abstinence Syndrome.新生儿戒断综合征的治疗干预措施。
Nurs Womens Health. 2019 Aug;23(4):357-365. doi: 10.1016/j.nwh.2019.05.006. Epub 2019 Jun 25.
8
Pharmacotherapy for Neonatal Abstinence Syndrome: Choosing the Right Opioid or No Opioid at All.新生儿戒断综合征的药物治疗：选择正确的阿片类药物或完全不使用阿片类药物。
Neonatal Netw. 2016;35(5):314-20. doi: 10.1891/0730-0832.35.5.314.
9
Breastfeeding promotion for management of neonatal abstinence syndrome.促进母乳喂养以管理新生儿戒断综合征
J Obstet Gynecol Neonatal Nurs. 2013 Sep-Oct;42(5):517-26. doi: 10.1111/1552-6909.12242. Epub 2013 Sep 4.
10
Buprenorphine: a newer drug for treating neonatal abstinence syndrome.丁丙诺啡：一种治疗新生儿戒断综合征的新药。
Neonatal Netw. 2012 May-Jun;31(3):178-83. doi: 10.1891/0730-0832.31.3.178.
引用本文的文献
1
Abnormal Morphology and Synaptogenic Signaling in Astrocytes Following Prenatal Opioid Exposure.产前阿片类药物暴露后星形胶质细胞的形态异常和突触发生信号。
Cells. 2024 May 14;13(10):837. doi: 10.3390/cells13100837.
2
Evaluating the Impact of Eat, Sleep, Console in Neonatal Abstinence Syndrome Treatment for Infants Exposed to Substance Use .评估“进食、睡眠、安抚”对物质使用暴露婴儿新生儿戒断综合征治疗的影响
J Pediatr Pharmacol Ther. 2024 Apr;29(2):151-158. doi: 10.5863/1551-6776-29.2.151. Epub 2024 Apr 8.
3
Forecasting Fetal Buprenorphine Exposure through Maternal-Fetal Physiologically Based Pharmacokinetic Modeling.通过基于生理药代动力学模型的母胎模型预测胎儿丁丙诺啡暴露情况。
Pharmaceutics. 2024 Mar 8;16(3):375. doi: 10.3390/pharmaceutics16030375.
4
5
Stability Study of a Compounded Sublingual Buprenorphine Solution for Neonatal Opioid Withdrawal Syndrome.用于新生儿阿片类药物戒断综合征的复方舌下丁丙诺啡溶液稳定性研究
J Pediatr Pharmacol Ther. 2023;28(8):710-713. doi: 10.5863/1551-6776-28.8.710. Epub 2023 Dec 12.
6
Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids.未来患有阿片类药物所致新生儿戒断综合征（NAS）的新生儿可通过遗传成瘾风险严重程度（GARS）测试进行评估，并有可能采用精准氨基酸脑啡肽酶抑制疗法（KB220）作为一线治疗方式，而非强效阿片类药物进行治疗。
J Pers Med. 2022 Dec 6;12(12):2015. doi: 10.3390/jpm12122015.
7
Neonatal opioid withdrawal syndrome: a review of the science and a look toward the use of buprenorphine for affected infants.新生儿阿片类药物戒断综合征：对科学的综述及对受影响婴儿使用丁丙诺啡的展望。
J Perinatol. 2022 Mar;42(3):300-306. doi: 10.1038/s41372-021-01206-3. Epub 2021 Sep 23.
8
Stability-indicating LC-MS Method for Determination of Stability of Extemporaneously Compounded Buprenorphine Oral Syringes for Neonatal Abstinence Syndrome.用于测定新生儿戒断综合征临时配制丁丙诺啡口服注射器稳定性的稳定性指示液相色谱-质谱法
J Pediatr Pharmacol Ther. 2021;26(4):395-404. doi: 10.5863/1551-6776-26.4.395. Epub 2021 May 19.
9
Clearance of buprenorphine during pregnancy and neonatal outcomes.孕期和新生儿结局中的丁丙诺啡清除率。
Arch Womens Ment Health. 2021 Dec;24(6):933-939. doi: 10.1007/s00737-021-01128-1. Epub 2021 Apr 16.
10
Clinical pharmacology and dosing regimen optimization of neonatal opioid withdrawal syndrome treatments.新生儿阿片类戒断综合征治疗的临床药理学和剂量方案优化。
Clin Transl Sci. 2021 Jul;14(4):1231-1249. doi: 10.1111/cts.12994. Epub 2021 May 1.
本文引用的文献
1
Comparison of Neonatal Abstinence Syndrome Treatment with Sublingual Buprenorphine versus Conventional Opioids.舌下丁丙诺啡与传统阿片类药物治疗新生儿戒断综合征的比较
Am J Perinatol. 2018 Mar;35(4):405-412. doi: 10.1055/s-0037-1608634. Epub 2017 Nov 7.
2
Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy.第711号委员会意见：孕期阿片类药物的使用与阿片类药物使用障碍
Obstet Gynecol. 2017 Aug;130(2):e81-e94. doi: 10.1097/AOG.0000000000002235.
3
Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome.丁丙诺啡用于治疗新生儿戒断综合征
N Engl J Med. 2017 Jun 15;376(24):2341-2348. doi: 10.1056/NEJMoa1614835. Epub 2017 May 4.
4
Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.阿片类药物替代治疗期间及之后的死亡风险：队列研究的系统评价和荟萃分析
BMJ. 2017 Apr 26;357:j1550. doi: 10.1136/bmj.j1550.
5
Buprenorphine for managing opioid withdrawal.丁丙诺啡用于管理阿片类药物戒断。
Cochrane Database Syst Rev. 2017 Feb 21;2(2):CD002025. doi: 10.1002/14651858.CD002025.pub5.
6
Disproportionality analysis of buprenorphine transdermal system and cardiac arrhythmia using FDA and WHO postmarketing reporting system data.使用美国食品药品监督管理局（FDA）和世界卫生组织（WHO）上市后报告系统数据对丁丙诺啡透皮贴剂与心律失常进行不成比例性分析。
Postgrad Med. 2017 Jan;129(1):62-68. doi: 10.1080/00325481.2016.1271698.
7
Review: The blood-brain barrier; protecting the developing fetal brain.综述：血脑屏障；保护发育中的胎儿大脑。
Placenta. 2017 Jun;54:111-116. doi: 10.1016/j.placenta.2016.12.005. Epub 2016 Dec 6.
8
Clinical effects of unintentional pediatric buprenorphine exposures: experience at a single tertiary care center.儿童意外暴露于丁丙诺啡的临床影响：一家三级医疗中心的经验
Clin Toxicol (Phila). 2017 Jan;55(1):12-17. doi: 10.1080/15563650.2016.1244337. Epub 2016 Oct 19.
9
The Association Between Breastfeeding and Length of Hospital Stay Among Infants Diagnosed with Neonatal Abstinence Syndrome: A Population-Based Study of In-Hospital Births.母乳喂养与诊断为新生儿戒断综合征的婴儿住院时间之间的关联：一项基于人群的住院分娩研究。
Breastfeed Med. 2016 Sep;11:343-9. doi: 10.1089/bfm.2016.0084. Epub 2016 Aug 16.
10
Improving Care for Neonatal Abstinence Syndrome.改善新生儿戒断综合征的护理
Pediatrics. 2016 May;137(5). doi: 10.1542/peds.2015-3835. Epub 2016 Apr 15.
Zotero 插件